ComPareNET
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial
- NCT05247905 ↗
- Active, not recruiting
- Alliance for Clinical Trials in Oncology
- Focused
We haven't built an HCP commentary report on ComPareNET (lutetium lu 177 dotatate, temozolomide and 1 more in Metastatic Pancreatic Neuroendocrine Tumor) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ComPareNET so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor; Unresectable Pancreatic Neuroendocrine Carcinoma
- Interventions
- Lutetium Lu 177 Dotatate; Capecitabine; Temozolomide; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (lutetium Lu 177 dotatate) · Experimental
- Arm II (capecitabine, temozolomide) · Experimental
- Enrollment
- 31
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Feb 16, 2023
- Primary completion
- Oct 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05247905 · updated Oct 20, 2026